These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28202508)

  • 1. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.
    Lu Y; Kwintkiewicz J; Liu Y; Tech K; Frady LN; Su YT; Bautista W; Moon SI; MacDonald J; Ewend MG; Gilbert MR; Yang C; Wu J
    Cancer Res; 2017 Apr; 77(7):1709-1718. PubMed ID: 28202508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.
    Saville KM; Al-Rahahleh RQ; Siddiqui AH; Andrews ME; Roos WP; Koczor CA; Andrews JF; Hayat F; Migaud ME; Sobol RW
    DNA Repair (Amst); 2024 Aug; 140():103700. PubMed ID: 38897003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
    Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 6. The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in
    Tateishi K; Higuchi F; Miller JJ; Koerner MVA; Lelic N; Shankar GM; Tanaka S; Fisher DE; Batchelor TT; Iafrate AJ; Wakimoto H; Chi AS; Cahill DP
    Cancer Res; 2017 Aug; 77(15):4102-4115. PubMed ID: 28625978
    [No Abstract]   [Full Text] [Related]  

  • 7. IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.
    Wang JB; Dong DF; Wang MD; Gao K
    Asian Pac J Cancer Prev; 2014; 15(1):427-32. PubMed ID: 24528069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
    Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
    Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
    Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
    Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
    Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
    Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
    Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
    Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
    Ohba S; Mukherjee J; See WL; Pieper RO
    Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
    Koncar RF; Chu Z; Romick-Rosendale LE; Wells SI; Chan TA; Qi X; Bahassi EM
    Oncotarget; 2017 Feb; 8(9):15827-15837. PubMed ID: 28178660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.
    Sun X; Turcan S
    Cells; 2021 May; 10(5):. PubMed ID: 34067729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
    Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
    Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
    Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
    Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.